Floatz logo

ABATACEPT RECOMBINANT

Anaplastic Large Cell Lymphoma

National Cancer Institute (NCI)protein_peptidePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

51 Active assets in the Anaplastic Large Cell Lymphoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Seagen Inc.
Phase 4BBB
Crizotinib
Pfizer
Phase 4BBB
Inno-206
City of Hope Medical Center
Phase 4BBB
Brentuximab Vedotin
Seagen Inc.
Phase 3BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BBB

View all 50 →

Same molecule, other indications

ABATACEPT RECOMBINANT is also rated in:

Primary Biliary CholangitisDormant
BB
Indicative ·
69 / 100
View asset →
acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
primary biliary cholangitisDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →